In this regard, the combination of EGFR-TKIs with anti-angiogenic drugs that induce the normalization of tumor vasculature has improved the clinical outcome of EGFR-mutant NSCLC patients, possibly also through an enhanced delivery of anti-EGFR agents to the target tumor sites [20,21,22,23]. Here, EGFR is linked to non-small cell lung carcinoma.